Multiple gestations are known to be at increased risk for pulmonary edema. Our objective was to characterize this morbidity in a cohort of triplet pregnancies.
INTRODUCTION
Pulmonary edema is a rare complication of normal pregnancy, occurring in 0.5% of cases, 1 but its incidence increases in the setting of obstetric complications like pre-eclampsia (2.9 2 to 3.4% 3 ) or treatment for preterm labor (as high as 5% 4 ). Multiple gestation may further exacerbate the condition. 5 Triplet pregnancies are at risk for both pre-eclampsia and preterm labor, [6] [7] [8] so one might suspect an increased incidence of pulmonary edema in triplet gestations. In general, studies of perinatal morbidity in triplet gestations have not emphasized pulmonary edema as a possible maternal complication, so the incidence and risk factors for this condition are difficult to ascertain from the current literature. The goal of this study was to describe the incidence and assess the risk factors for pulmonary edema in a cohort of triplet pregnancies.
METHODS
By review of delivery records, 71 triplet pregnancies were identified that were managed by members of the Georgetown University Hospital Division of Maternal-Fetal Medicine from 1993 through 2002. Maternal charts were abstracted for demographic information and obstetric complications.
Pulmonary edema as an outcome was identified by patient's complaint of dyspnea and evidence of oxygen desaturation in the presence of either chest X-ray finding consistent with fluid overload or resolution after empiric i.v. furosemide therapy or both. Severe pulmonary edema was defined as need for i.v. furosemide to resolve.
Clinical characteristics of those patients including maternal age, gestational age at delivery, birthweights, tocolytic use, timing of pulmonary edema and comorbid conditions between those patients developing pulmonary edema were compared to those who did not using Fisher's exact test, w 2 and Student's t-test with a two-tailed p<0.05 considered significant. Among all patients treated with magnesium sulfate, those who developed pulmonary edema were more likely than those who did not to have been treated for pre-eclampsia than preterm labor [6/ 14 (42.9%) vs 7/33 (21.2%), p ¼ 0.3]. The difference reached statistical significance when only the subset of the more severe cases of pulmonary edema was analyzed (those needing i.v. furosemide to resolve) (6/10 (60%) vs 7/33 (21.2%), p ¼ 0.04). Of interest, five of the six cases of pre-eclampsia-associated pulmonary edema occurred postpartum. In those patients receiving antepartum magnesium sulfate therapy, the gestational age at initiation of treatment was similar between those developing pulmonary edema and those who did not (29.0±3.7 vs 28.0±4.1, p ¼ 0.44).
RESULTS

Of
SIGNIFICANCE
We have found that patients with triplet pregnancy receiving magnesium sulfate, having pre-eclampsia or fetal growth restriction are at increased risk for pulmonary edema, particularly in its worse clinical presentation (i.e. requiring i.v. diuresis). Pulmonary edema is rare in a general obstetric population, occurring in about 0.05% of pregnancies. 1 However, this rate Multiple gestation has been implicated in pulmonary edema because of the increase in blood volume associated with this condition. 3 In twin gestations, there is an additional 33% increase in blood volume over the typical 50% increase seen in singleton gestation. 9 This observation may explain the several reports associating pulmonary edema with multiple gestation, particularly in the setting of magnesium sulfate or beta-mimetic tocolysis for preterm labor. [10] [11] [12] Tocolytic therapy may be an independent risk factor for pulmonary edema, particularly beta-mimetic therapy. Multiple clinical reports have implicated terbutaline in the development of maternal pulmonary edema, [13] [14] [15] [16] particularly with concurrent steroid administration or presence of infection. The physiologic explanation for this is probably rooted in the phenomenon of plasma volume expansion secondary to sodium retention. 17 Magnesium sulfate therapy in the setting of preterm labor has also been associated with maternal pulmonary edema. 1, 10, 12 There is a subgroup of preterm labor patients that seem more disposed to pulmonary edema following magnesium sulfate therapy. A study of 257 patients (81% singletons) with advanced cervical dilation (3 cm or more) and magnesium sulfate tocolysis identified a 5% incidence of mild pulmonary edema. 4 Out of concern for reports implicating magnesium sulfate therapy, Yeast et al. 3 prospectively measured colloid osmotic pressure in 294 patients (both singleton and multiple gestations) receiving parenteral magnesium sulfate for tocolysis or seizure prophylaxis. This measurement describes the ability of the intravascular space to retain and is felt to be a simple assessment of pulmonary edema risk. This study found that the physiologic effects of magnesium sulfate result in consistently lower colloid osmotic pressures when it is used for seizure prophylaxis in the setting of pre-eclampsia as opposed to for tocolysis. There were only four cases of pulmonary edema (3.2% incidence), all in the setting of magnesium sulfate therapy for seizure prophylaxis and none in patients treated for preterm labor.
When evaluating the association between magnesium sulfate infusion and pulmonary edema in our study, it is important to remember that this is a retrospective study, so a uniform policy of administration cannot be guaranteed. The general protocol at our hospital is to give 4 g intravenous loads and then give 2 g/hour. Urine output is monitored, as are the patient's reflexes, every 2 hours. In the case of pre-eclampsia, levels are sent 6 hours after initiation to insure treatment in the therapeutic range. In the case of preterm labor, Mg infusions are increased if tocolysis is not achieved with a 2 g/hour dose; Mg levels are not routinely sent.
In other retrospective studies, investigators have documented the incidence of pulmonary edema in the setting of pre-eclampsia, which may range from 2.9% in the case of severe pre-eclampsia 2 to 6% in the setting of HELLP syndrome. 18 Benedetti et al. 19 performed invasive hemodynamic measurements on 10 patients with pre-eclampsia and pulmonary edema and found a decrease in colloid osmotic pressure. Of interest, eight of the patients developed pulmonary edema in the postpartum period. It is impossible to differentiate the effects of magnesium sulfate therapy from that of the underlying pre-eclamptic disease in these patients. In summary, we found a high incidence of pulmonary edema in triplet gestations (22.6%). Most of these cases were mild and resolved with minimal interventions. Others describing perinatal outcomes in triplet pregnancies have not reported maternal pulmonary edema as an outcome 7, 20, 21 or reported a very low incidence (2.1%). 22 It is possible that our definition of pulmonary edema is broader than others and includes cases unlikely to be reported by other investigators.
It is not surprising that there is such a high incidence of pulmonary edema in our population of triplets when one considers the multiple risk factors present: multiple gestation, high likelihood of preterm labor necessitating magnesium sulfate tocolysis and higher incidence of pre-eclampsia. The addition of the volume shifts seen postdelivery exacerbated the condition for some patients. A theory of multifactorial pulmonary edema has been advanced before. 5 Like other investigators, we found that magnesium sulfate therapy for pre-eclampsia was a greater risk factor for more severe pulmonary edema when compared to its use for preterm labor. Consistent with this was the interesting finding that babies delivered to mothers with pulmonary edema were smaller than those who did not, despite similar gestational ages at delivery. This suggests that the alterations in maternal pulmonary endothelial permeability may be another consequence of poor placental implantation similar to pre-eclampsia and fetal growth restriction.
Despite the relationship between pulmonary edema and magnesium sulfate use for seizure prophylaxis in our triplet population, we would be hesitant to specifically recommend phenytoin over magnesium sulfate given that the latter drug has been shown to be superior in terms of seizure prevention in a randomized controlled trial of pre-eclamptic patients. 23 In our small series of patients, the pulmonary edema was easily controlled and without sequelae; it seems prudent to make clinicians alert to the complication rather than to risk eclamptic seizures. Certainly if a patient developed pulmonary edema in the setting of preeclampsia and was anticipated to need a greater duration of therapy with magnesium sulfate than normal, consideration should be given on a case-by-case basis to fluid restriction (i.e. double concentration of the magnesium sulfate infusion) or phenytoin treatment.
It is also important to remember that pulmonary edema occurred in the setting of magnesium sulfate for tocolysis as well. Aggressive tocolysis, particularly past 33 weeks gestation, should be undertaken with caution as the benefits to the fetuses of further delay in delivery may not outweigh the maternal risk.
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